Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) updated its FY23 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $5.10-5.25 for the period, compared to the consensus estimate of $4.97. The company issued revenue guidance of $124-126 million, compared to the consensus revenue estimate of $127.17 million. Wall Street Analyst Weigh […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) updated its FY 2023 earnings guidance on Tuesday. The company provided EPS guidance of $4.85-$5.00 for the period, compared to the consensus EPS estimate of $4.63. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $131.17 million. Ligand Pharmaceuticals also updated […]
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Earnings Results, Beats Expectations By $0.66 EPS etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Rating) had its target price upped by HC Wainwright from $135.00 to $144.00 in a report released on Friday, The Fly reports. Other equities analysts also recently issued reports about the company. StockNews.com raised Ligand Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Rating) Director John W. Kozarich sold 6,408 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $76.56, for a total value of $490,596.48. Following the transaction, the director now directly owns 42,213 shares of the company’s stock, […]